Latest news with #CPT®
Malaysian Reserve
7 days ago
- Business
- Malaysian Reserve
2026 Medicare Physician Fee Schedule Rates Set for Scalp Cooling CPT Codes
SAN DIEGO, July 15, 2025 /PRNewswire/ — Cooler Heads, a health tech company dedicated to making scalp cooling more accessible and affordable for people undergoing chemotherapy, celebrates a major milestone in the effort to expand access to their hair-preserving treatment. The Centers for Medicare & Medicaid Services (CMS) has released its 2026 Medicare Physician Fee Schedule (MPFS) Proposed Rule, which includes three new Category I CPT® codes for mechanical scalp cooling, each assigned a proposed payment rate. This is the first time scalp cooling has been included in the Medicare Physician Fee Schedule, marking a critical step forward in establishing consistent reimbursement. 'This decision is important for patients suffering from hair loss, a devastating and visible side effect of chemotherapy,' said Kate Dilligan, Founder and CEO of Cooler Heads. 'These new codes and proposed rates are a positive step towards helping all patients undergoing treatment for solid tumor cancers preserve their identity during treatment.' CMS has proposed payment rates for three new CPT® codes related to mechanical scalp cooling. The first code, covering the initial fitting of the scalp cooling cap and patient education, would be reimbursed at $1,701. The second code, for the pre-infusion cooling period, is proposed at $10 per treatment. The third code, covering the post-infusion cooling period in 30-minute increments, would be reimbursed at $6 per unit. The new codes do not apply to manual cold caps, highlighting the importance of FDA-cleared mechanical scalp cooling systems like Amma™. This decision also sets a precedent for private insurers to develop their own coverage policies, increasing the likelihood of broader access to patients. After the public comment period concludes on September 12, 2025, and any subsequent updates are made, CMS is expected to release the Final Rule in November 2025. The revised Medicare Physician Fee Schedule (MPFS) rates and updated CPT codes will take effect on January 1, 2026. This timeline presents an exciting opportunity for Cooler Heads to collaborate with health systems. Contact:press@ About Cooler Heads: Cooler Heads, based in San Diego, provides evidence-based products, content, and services that cancer patients need to manage the challenging side effects of treatment. Founded by a cancer survivor, Cooler Heads is driven by the mission to reduce the physical and emotional toll of cancer treatment, offering tools like Amma to improve the quality of life for patients.
Yahoo
25-02-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Royal Biologics Announces Strategic Partnership With Coldplasmatech GmbH
This Press Release updates an error in the sub headline Strategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Care HACKENSACK, NEW JERSEY / / February 25, 2025 / Royal Wound-X, a division of Royal Biologics committed to pioneering advanced wound care solutions, and Coldplasmatech GmbH, an innovator in medical cold plasma technology, today announce their strategic partnership aimed at transforming the treatment landscape for complex and chronic wounds worldwide. Chronic and acute wounds, including those complicated by multi-resistant infections, affect nearly one billion people globally and represent an annual healthcare cost of approximately $50 billion in the United States alone. Addressing this urgent medical challenge, Coldplasmatech's innovative Cold Atmospheric Plasma (CAP) technology, consisting of the CPT®cube (an automated control device) and CPT®patch (a specialized wound applicator), provides an effective, rapid, and safe therapy for complex wounds. It is registered as class IIb medical device in the European Union but is not yet approved in the United States. Dr. Carsten Mahrenholz, CEO of Coldplasmatech GmbH, states: "Our partnership with Royal Biologics marks a critical milestone. Chronic wounds remain a global healthcare burden, and our CPT® cold plasma therapy offers a transformative solution-combating multi-drug-resistant bacteria, and significantly improving patient outcomes." Salvatore Leo, CEO and founder of Royal Biologics and Royal Wound-X, who will join Coldplasmatech's board of directors, and serve as Chief Executive Officer of Cold Plasma U.S.A emphasizes the significance: "We are thrilled to announce our strategic partnership with Coldplasmatech GmbH. Chronic and acute wounds, with their known antimicrobial resistance, significantly impact society and healthcare costs. We are looking at a paradigm shift in the way health practitioners treat chronic wounds and anti-microbial resistance. CPT® cold plasma therapy will truly change the way we think about chronic wound care moving forward. Our partnership is a historic moment for patients suffering from chronic wounds." said Leo. Innovative Technology for Enhanced Wound Healing and Infection Management Inspired by science fiction's dermal regenerators, Coldplasmatech's patented CPT® system utilizes ionized gas to create a bioactive healing environment. The plasma effectively reduces bacterial burden, including antibiotic-resistant pathogens, and enhances cellular regeneration. With a simple two-minute application, the therapy integrates seamlessly into standard clinical workflows and can be combined with other advanced treatments, such as negative pressure therapy and skin substitute matrices. The technology is currently deployed at renowned medical institutions, including Hannover Medical School and University Heart Center Hamburg, and has been shown to help in successfully treating severe burns, surgical wounds, and chronic wounds. Prof. Dr. Markus Barten from the University Heart Center Hamburg summarizes: "The simple handling allows for quick and painless wound care with high effectiveness, to the delight of patients." About Coldplasmatech GmbH Founded in 2015 as a spin-off of the Leibnitz Institute for Plasma Research, Coldplasmatech GmbH is based in Greifswald, Germany. The company has earned international recognition for its CPT® cold plasma therapy, receiving multiple prestigious awards, including the German Innovation Award, Bavarian Innovation Award and IQ Innovation Award. Coldplasmatech is currently conducting the world's largest randomized controlled trial (RCT) on cold plasma therapy -the POWER Study- funded by the German Federal Ministry of Education and Research. For further information: About Royal Biologics Royal Biologics, headquartered in Hackensack, NJ, was founded in 2015 and specializes in the development, licensing, production, and distribution of orthobiologic products designed to enhance healing across various clinical settings, including orthopedics, sports medicine, spine surgery, wound care, and regenerative medicine. Their comprehensive product portfolio includes autologous advanced biologics, cellular bone grafts, traditional bone grafts, advanced synthetics, and specialized wound care products. Under the leadership of founder Salvatore Leo (CEO) and with backing from Granite Creek Capital Partners, Royal Biologics is committed to delivering innovative biologic solutions that improve patient outcomes. For further information: Contact Information Royal Support Team support@ SOURCE: Royal Biologics View the original press release on ACCESS Newswire Sign in to access your portfolio
